Topical Transforming Growth Factor-β3 in the Prevention or Alleviation of Chemotherapy-Induced Oral Mucositis in Patients with Lymphomas or Solid Tumors

Journal of Immunotherapy

Volumn 24, Issue 4, 2001, Pages 384-388

  Foncuberta, M C ^a   Cagnoni, P J ^a   Brandts, C H ^a   Mandanas, R ^a   Fields, K ^a   Derigs, H G ^a   Reed, E ^a   Sonis, S T ^b   Fay, J ^b   LeVeque, F ^b   Pouillart, P ^b   Schrezenmeier, H ^b   Emmons, R ^b   Thiel, E ^b  

^a University of Colorado Health Sciences   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

High dose chemotherapy; Objective scoring system for oral mucositis; Oral mucositis

Indexed keywords

ANTINEOPLASTIC AGENT; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG FORMULATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOTHERAPY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOUTHWASH; MUCOSA INFLAMMATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOLID TUMOR; TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; LYMPHOMA; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTHWASHES; NEOPLASMS; PLACEBOS; PREGNANCY; TRANSFORMING GROWTH FACTOR BETA;

EID: 17944368738     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200107000-00014     Document Type: Article

References (28)

1. Sonis ST. Oral complications of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice in Oncology, 3rd ed, vol 2. Philadelphia: Lippincott, 1989, pp 2144-52.
2. Hudis CA, Munster PN. High-dose therapy for breast cancer. Semin Oncol 1999; 26: 35-47.
3. Nieto Y, Cagnoni PJ, Jones RB. Standard versus high-dose therapy in 10+ breast cancer. J Clin Oncol 1998; 16: 810-1.
4. Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five year results. J Clin Oncol 1997; 15: 2312-21.
5. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-5.
6. National Institutes of Health Consensus Development Panel. Consensus statement: oral complications of cancer therapies: diagnosis, prevention and treatment. National Cancer Institutes Monograph 1990;Vol. 9.
7. Sonis S, Clark J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology 1991; 5: 11-8.
8. Sonis ST, Costello KA. A database for mucositis induced by cancer chemotherapy. Oral Oncol 1995; 31B: 258-60.
9. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495-508.
10. Pico JL, Vaila-Garavito A, Naccache P. Mucositis: its occurrence, consequences and treatment in the oncology setting. Oncologist 1998; 3: 446-51.
11. Sonis ST. Oral complications of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice in Oncology, 3rd ed, vol 2. Philadelphia: Lippincott, 1989, pp 2144-52.
12. Barker GJ. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer 1999; 7: 17-20.
13. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol 1996; 14: 838-47.
14. Peterson DE. Research advances in oral mucositis. Curr Opin Oncol 1999; 11: 261-6.
15. Büntzel J, Schuth J, Küttner K, Glatzel M. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 1998; 6: 155-60.
16. Loury DJ, Embree JR, Steinberg DA, Sonis ST, Fiddes JC. Effect of local application of the antimicrobial IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87: 544-51.
17. Danilenko DM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol 1999; 27: 64-71.
18. Sonis S, Edwards L, Lucey C. The biological basis for attenuation of mucositis: the example of IL-11. Leukemia 1999; 18: 831-4.
19. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the orothelium. N Engl J Med 1988; 318: 1414-22.
20. Chi KW, Chen CH, Chan WK, et al. Effect of granulocyte-macrophage colony stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil and leucovorin chemotherapy. J Clin Oncol 1995; 13: 2620-28.
21. Wagner W, Alfrink M, Haus U, Matt J. Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer. Anticancer Res 1999; 19B: 799-803.
22. Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation. Cancer Res 1995; 55: 1452-7.
23. Sonis ST, Van Vugt AG, O'Brien JP, et al. Transforming growth factor β3-mediated modulation of cell cycling and attenuation of 5-FU induced oral mucositis. Oral Oncol 1997; 33: 47-54.
24. Wymenga AN, van der Graaf WTA, Hofstra LS, et al. Phase I study of transforming growth factor-β3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res 1999: 5: 1363-8.
25. Novartis Pharma AG. A Direct Immunoassay for the Assessment of Antibody Formation in Human and Animal Plasma After Administration of CGP 46614. Report DMPK (CH) 1997/267. Drug Metabolism and Pharmacokinetics. Novartis Pharma AG: Basel, 1997.
26. Novartis Pharma AG. A Direct Immunoassay for the Assessment of Antibody Formation in Human and Animal Plasma After Administration of CGP 46614. Report DMPK (CH) 1997/267. Drug Metabolism and Pharmacokinetics. Novartis Pharma AG: Basel, 1997.
27. Niland JC. Hypothesis testing of time-dependent recurrent events. Stat Med 1987; 6: 689-99.
28. Beelen GM, Appel MJ, Fenenter van Vlissingen JM, Rose A, Emmons RP, Arvinte T. In vivo functional assay of TGF-β3 on pig buccal epithelium: dose and formulation dependence. (Manuscript in preparation).